Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics

Rhea-AI Summary

Nimble Therapeutics has expanded its strategic research collaboration with Incyte to discover additional novel peptide therapies. CEO Jigar Patel highlighted this collaboration as a validation of Nimble's capabilities in peptide therapeutics. Under the agreement, Nimble will receive an upfront payment and reimbursement for certain research costs and may be eligible for milestone payments and royalties. Incyte retains exclusive rights to develop and commercialize any peptides discovered during the collaboration and has options for further expansion.

Positive

• Expansion of the collaboration allows for discovery of additional novel peptide therapies.
• Nimble receives upfront payment and reimbursement, enhancing cash flow.
• Potential for milestone payments and royalties offers financial upside.

Negative

• None.

MADISON, Wis.--(BUSINESS WIRE)-- Nimble Therapeutics, a biotechnology company revolutionizing the discovery and development of peptide therapeutics, today announced their strategic research collaboration with Incyte (NASDAQ: INCY) has been expanded to include discovery of additional novel peptide therapies.

“Nimble looks forward to building upon on the already strong collaboration between the Nimble and Incyte scientific teams. The expansion of the collaboration serves as yet another important validation of Nimble’s powerful capabilities and approach towards engineering the next generation of peptide therapeutics,” said Jigar Patel, CEO and Founder of Nimble Therapeutics.

Under the terms of the agreement, Nimble will receive an upfront payment and reimbursement of certain research program costs and may become eligible for downstream milestone payments and royalties. Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration and has an option to further expand the collaboration to include additional targets.

About Nimble Therapeutics

Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful analytics to efficiently and intelligently discover and develop next generation peptide therapeutics.

Connect with us on LinkedIn at www.linkedin.com/company/nimble-therapeutics or visit our website at www.nimbletherapeutics.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005143/en/

Nimble Therapeutics, Inc.

Brad Garcia, Ph.D.

Vice President, Corporate Development

info@nimbletherapeutics.com

Source: Nimble Therapeutics

FAQ

What does the collaboration between Nimble Therapeutics and Incyte involve?

The collaboration focuses on discovering additional novel peptide therapies.

What financial benefits will Nimble Therapeutics receive from the collaboration with Incyte?

Nimble will receive an upfront payment, reimbursement for research costs, and may earn milestone payments and royalties.

What are Incyte's rights under the collaboration with Nimble Therapeutics?

Incyte has exclusive rights to develop and commercialize any peptides discovered during the collaboration.

Who is the CEO of Nimble Therapeutics?

Jigar Patel is the CEO and Founder of Nimble Therapeutics.

What is the significance of the collaboration between Nimble and Incyte for investors?

The collaboration represents a validation of Nimble's capabilities and provides potential financial benefits through payments and royalties.